Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2016 were as follows:

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

Sales of Available-for-Sale Securities

The following table summarizes sales of available-for-sale securities for the years ended September 30, 2016, 2015 and 2014 (in thousands):

	2016			2015			2014
Proceeds from sales	$	2,498		$	22,199		$	162,673
Gross realized gains	$	—		$	548		$	134
Gross realized losses	$	(2	)	$	(73	)	$	(1	)

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2016		2015
Raw materials	$	1,766	$	1,264
Work in-process		492		213
Finished products		1,321		1,502
Total	$	3,579	$	2,979

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2016			2015
	(In years)
Land	N/A	$	4,359		$	4,359
Laboratory fixtures and equipment	3 to 10		15,243			12,941
Buildings and improvements	3 to 20		19,589			16,444
Office furniture and equipment	3 to 10		3,948			3,473
Construction-in-progress			3,441			1,168
Less accumulated depreciation			(26,979	)		(25,417	)
Property and equipment, net		$	19,601		$	12,968

Summary of Other Assets

Other assets consist principally of the following as of September 30 (in thousands):

	2016		2015
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		149		—
Other assets, net	$	628	$	479

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2016
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

	2015
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	5,132	$	(4,363	)	$	769
Core technology		8.0		530		(530	)		—
Non-compete		5.0		230		(12	)		218
Patents and other	16.8			2,321		(1,128	)		1,193
Subtotal				8,213		(6,033	)		2,180
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,793	$	(6,033	)	$	2,760

Estimated Amortization Expense

Based on the intangible assets in service, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility as of September 30, 2016, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2017	$	2,580
2018		2,534
2019		2,534
2020		2,358
2021		2,219

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the year ended September 30, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device		Total
Balance as of September 30, 2015	$	8,010	$	—	$	8,010
Additions (See Note 3)		—		17,892		17,892
Foreign currency translation adjustment		—		653		653
Balance as of September 30, 2016	$	8,010	$	18,545	$	26,555

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share (in thousands):

	2016		2015		2014
Net income from continuing operations available to common shareholders	$	9,985	$	11,947	$	12,207
Basic weighted average shares outstanding		12,998		13,029		13,632
Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units and performance    shares		221		260		244
Diluted weighted average shares outstanding		13,219		13,289		13,876